• 08FEBBBB-8B6A-47BB-9A6DD95731A56255

Data from Brainomix’s Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.

CEO Update - 25 March 2024

I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

AI in life sciences: an evolving risk landscape

In this article, Marsh’s Life Sciences industry practice leader Jenny Yu and experts from Kennedys take a look at the topic of AI in the life sciences sector, the associated risks regulation and potential liability issues, as well as how companies can seek to ‘future-proof’ themselves in the face of rapid change.

Advanced Therapy Treatment Centre network to bolster clinical trial infrastructure in the UK

The NIHR, Innovate UK, the Advanced Therapy Treatment Centre Network and the CGT Catapult announce a £17.9 million strategic initiative to enhance the UK environment for advanced therapy medicinal product (ATMP) clinical trials and to keep the UK as a location of choice for advanced therapy research.

Notice of Allowance for Significant POLB 001 Patent in United States

Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio

Empowering innovation: Cancer Research Horizons recognises trailblazers in oncology

Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its second Innovation & Entrepreneurship Awards.